Bayer enlists Arvinas on two-pronged protein degradation effort, foraying into agtech
Arvinas has inked another Big Pharma partnership to get their protein degradation engines revving — for both humans and crops.
All told, the German conglomerate is wagering $115 million on the potential of Arvinas’ tech platform, which uses an E3 ligase to tag target proteins with an ubiquitin, flushing these disease culprits down the cell’s natural “garbage disposal.” And Bayer is in for the whole package, with a collaboration, an equity investment and a joint venture in play.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.